公开(公告)号：US20190309091A1

公开(公告)日：2019-10-10

申请号：US16450186

申请日：2019-06-24

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Michael Gerg ,  Lars Hillringhaus ,  Klaus Hirzel ,  Caroline Dorothea Hojer ,  Hans-Peter Josel ,  Christoph Seidel ,  Michael Schraeml ,  Leopold Von Proff

IPC: C07K16/44 ,  G01N33/543

Abstract: The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as disclosed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.

公开(公告)号：US20190324025A1

公开(公告)日：2019-10-24

申请号：US16450181

申请日：2019-06-24

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Michael Gerg ,  Dieter Heindl ,  Lars Hillringhaus ,  Klaus Hirzel ,  Caroline Dorothea Hojer ,  Florian Huber ,  Hans-Peter Josel ,  Thomas Meier ,  Michael Schraeml ,  Edgar Voss

IPC: G01N33/543 ,  C07K16/44

Abstract: The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as disclosed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.

公开(公告)号：US20250155441A1

公开(公告)日：2025-05-15

申请号：US18951180

申请日：2024-11-18

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Michael Gerg ,  Lars Hillringhaus ,  Ute Jucknischke ,  Anna Christine Muth ,  Tobias Oelschlaegel ,  Boris Pinchuk ,  Michael Schraeml ,  Joanna Siebenhaar ,  Laurence Thirault

IPC: G01N33/574 ,  C07K16/18

Abstract: The present invention relates to monoclonal antibodies and antigen binding fragments that specifically bind to α-1,6-core-fucosylated alpha-fetoprotein (AFP), which is the core component of AFP-L3. Thus, the antibodies and antigen binding fragments provided herein may also be referred to as AFP-L3 antibodies. Also provided are polynucleotides encoding the antibodies or antigen binding fragments of the invention, host cells expressing the antibodies and antigen binding fragments of the invention, methods for producing the antibodies and antigen binding fragments of the invention, and uses of the antibodies and antigen binding fragments of the invention. Also provided herein is a pretreatment agent facilitating the binding of the antibodies and antigen binding fragments of the invention to α-1,6-core-fucosylated AFP. The present invention further relates to kits comprising the antibodies and antigen binding fragments of the invention and optionally the pretreatment agent of the invention.

公开(公告)号：US20230333095A1

公开(公告)日：2023-10-19

申请号：US18339799

申请日：2023-06-22

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Maksim Fomin ,  Dieter Heindl ,  Lars Hillringhaus ,  Hannes Kuchelmeister ,  Mohamed Yosry Hassan Mohamed ,  Tobias Oelschlaegel ,  Sona Simonyiova

IPC: G01N33/533 ,  G01N33/68 ,  C07F15/02

CPC classification number: G01N33/533 ,  G01N33/6887 ,  C07F15/025 ,  G01N2800/325

Abstract: The present invention relates to a method for determining at least one analyte of interest. The present invention further relates to a kit, a complex, a method to synthesize a complex and the use thereof for detecting the analyte of interest in the sample.

公开(公告)号：US12025613B2

公开(公告)日：2024-07-02

申请号：US17551723

申请日：2021-12-15

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Michael Gerg ,  Dieter Heindl ,  Lars Hillringhaus ,  Klaus Hirzel ,  Caroline Dorothea Hojer ,  Florian Huber ,  Hans-Peter Josel ,  Thomas Meier ,  Michael Schraeml ,  Edgar Voss

IPC: G01N33/543 ,  C07K16/44

CPC classification number: G01N33/54306 ,  C07K16/44

Abstract: The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as discloed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.

公开(公告)号：US20230340147A1

公开(公告)日：2023-10-26

申请号：US18187502

申请日：2023-03-21

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Magdalena Swiatek-de Lange ,  Joanna Siebenhaar ,  Carol Jones ,  Thomas Pritchett ,  Andrea Muranyi ,  Caroline Dorothea Hojer ,  Michael Gerg ,  Lars Hillringhaus ,  Gloria Tabares ,  Christian Roessler ,  Michael Schraeml ,  Shalini Singh ,  Theresa Kott

IPC: C07K16/30 ,  G01N33/574 ,  G01N1/30

CPC classification number: C07K16/3069 ,  G01N33/57434 ,  G01N1/30 ,  C07K2317/41 ,  G01N2001/302 ,  C07K2317/33 ,  C07K2317/92

Abstract: The present invention relates to an antibody or an antigen binding fragment thereof that specifically binds to α-1,6-core-fucosylated prostate specific antigen (PSA) and partial sequences thereof comprising the α-1,6-core-fucose residue. The antibodies and antigen binding fragments significantly discriminate between core-fucosylated PSA or core-fucosylated PSA partial sequences and other glycosylated PSA species and partial sequences thereof lacking the core-fucose residue, including aglycosylated PSA, as well as core-fucosylated glycan in other contexts. The present invention further relates to nucleic acid molecules encoding the light chain variable region or the heavy chain variable region of the antibody of the invention, as well as vectors comprising said nucleic acid molecules. The invention also relates to a host cell comprising the vector(s) of the invention, as well as to methods for the production of an antibody or antigen binding fragment of the invention comprising culturing the host cell of the invention under suitable conditions and isolating the antibody produced. Furthermore, the present invention relates to an antibody obtainable by the method of the invention, to a composition comprising at least one of the antibody or antigen binding fragment of the invention, the nucleic acid molecule of the invention, the vector of the invention, the host cell of the invention or the antibody produced by the method of the invention. The present invention also relates to the use of an antibody or antigen binding fragment of the invention for detecting and discriminating core-fucosylated PSA or core-fucosylated partial sequences thereof in biological samples.

公开(公告)号：US20230055005A1

公开(公告)日：2023-02-23

申请号：US17821937

申请日：2022-08-24

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Bernhard Eckert ,  Michael Gerg ,  Johann Karl ,  Martin Kaufmann ,  Julia Riedlinger ,  Magdelena Swiatek-de-Lange ,  Lars Hillringhaus ,  Klaus Hirzel ,  Marcus-Rene Lisy

IPC: C07K16/36 ,  G01N33/574 ,  G01N33/86

Abstract: The present disclosure relates to specific binding agents binding to different PIVKA-II forms as compared to antibodies known so far in the art. The present disclosure also relates to methods of using the specific binding agents to detect the presence of PIVKA-II.

公开(公告)号：US20230095167A1

公开(公告)日：2023-03-30

申请号：US17801469

申请日：2021-02-19

Applicant: Universiteit Maastricht ,  Academisch Ziekenhuis Maastricht ,  Roche Diagnostics Operations, Inc.

Inventor： Alfred Engel ,  Michael Gerg ,  Ute Jucknischke ,  Johann Karl ,  Peter Kastner ,  Thomas Meier ,  Lars Hillringhaus ,  Ulrich Schotten ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen ,  André Ziegler ,  Roberto Latini ,  Jennifer Marie Theresia Anna Meessen

IPC: G01N33/74 ,  G01N33/68

Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP10 in a sample from the subject, and comparing the amount of BMP10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP 10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP10-type peptide in a sample from a subject. The present invention further pertains to antibodies which bind to one or more BMP10-type peptides such as NT-proBMP10.

公开(公告)号：US11466098B2

公开(公告)日：2022-10-11

申请号：US16740778

申请日：2020-01-13

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Bernhard Eckert ,  Michael Gerg ,  Johann Karl ,  Martin Kaufmann ,  Julia Riedlinger ,  Magdelena Swiatek-de Lange ,  Lars Hillringhaus ,  Klaus Hirzel ,  Marcus-Rene Lisy

IPC: C07K16/36 ,  G01N33/574 ,  G01N33/86

Abstract: The present disclosure relates to specific binding agents binding to different PIVKA-II forms as compared to antibodies known so far in the art. The present disclosure also relates to methods of using the specific binding agents to detect the presence of PIVKA-II.